Centessa Pharmaceuticals Limited (CNTA)
After hours:
| Previous close | 9.40 |
| Open | 9.58 |
| Bid | 8.00 x 1400 |
| Ask | 9.61 x 800 |
| Day's range | 9.06 - 9.90 |
| 52-week range | 8.47 - 26.90 |
| Volume | |
| Avg. volume | 215,367 |
| Market cap | 841.472M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the ALERT Study who previously discontinued JYNARQUE® due to liver toxicity successfully titrated to maintenance dose of lixivaptan; no subjects met pre-specified stopping criteria; no cases of suspected drug-induced liver injury (DILI) ~ ~ Issuance of new patent would cover use of lixivaptan in ADPKD throug
- Globe Newswire
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 20, 2021. The NASDAQ Biotechnology Index contains securities of NASDA
- Globe Newswire
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (“ABR”) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ Announced proof-of-mechanism data from first three PiMZ subjects dosed in Phase 1 Part B study evaluating ZF874 for the treatment of Alpha-1 Antitrypsin Deficiency (“AATD”) ~ ~ Announced collabo
